HONG KONG MEDICAL JOURNAL 香港醫學雜誌

SUPPLEMENTARY INFORMATION

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to:

X Li, Swathi Pathadka, Kenneth K Man, Ian CK Wong, Esther WY Chan. Budget impact of introducing tofacitinib to the public hospital formulary in Hong Kong, 2017-2021. Hong Kong Med J 2019;25:Epub 29 May 2019. http://doi.org/10.12809/hkmj187673

APPENDIX 1. Projected number of patients, 2017-2022



Abbreviation: DMARDs = disease-modifying anti-rheumatic drugs

APPENDIX 2. Summary of base-case scenario assumptions

Clinical assumptions

1. Remission and treatment failure were disregarded.
2. Identical efficacy and safety profiles were maintained for all treatments.
3. The 1-year retention rate was 80% for tofacitinib, whereas it was 100% for all biologic treatments.
4. Patients who discontinued tofacitinib would switch to a biologic treatment, on the basis of its market share.
5. All treatments had 100% compliance.

Economic assumptions

1. Treatment monitoring costs (eg, laboratory tests, rheumatology visits, X-rays, and cardiology and pulmonology monitoring assays) were not considered.
2. Indirect costs were not considered.
3. Costs of conventional synthetic disease-modifying antirheumatic drugs were not considered, as these comprise general drugs in the formulary.
4. Medication costs were identical throughout the 5-year period.
5. No cost inflation was considered.

 @2019 Hong Kong Academy of Medicine. All rights reserved

APPENDIX 3. Projected market share in the base-case scenario (a) without tofacitinib and (b) with tofacitinib, 2017-2021

(a)



	2017	2018	2019	2020	2021
Certolizumab (Cimzia)	1.4%	3.0%	6.5%	13.4%	25.4%
Abatacept (Orencia)	13.1%	15.0%	16.8%	18.0%	17.7%
Infliximab (Remicade)	4.9%	4.0%	3.2%	2.4%	1.7%
Golimumab (Simponi)	13.7%	14.1%	14.1%	13.5%	11.8%
Adalimumab (Humira)	10.1%	8.7%	7.3%	5.8%	4.3%
Tocilizumab (Actemra)	28.8%	29.0%	28.3%	26.4%	22.7%
Etanercept (Enbrel)	28.0%	26.1%	23.7%	20.5%	16.3%

 @2019 Hong Kong Academy of Medicine. All rights reserved

APPENDIX 3. (cont'd)

(b)



	2017	2018	2019	2020	2021
Tofaci:nib (Xeljanz)	4.4%	7.2%	9.0%	10.1%	10.7%
Certolizumab (Cimzia)	1.3%	2.8%	6.0%	12.1%	22.7%
Abatacept (Orencia)	12.5%	14.0%	15.3%	16.2%	15.8%
Infliximab (Remicade)	4.7%	3.7%	2.9%	2.2%	1.5%
Golimumab (Simponi)	13.1%	13.1%	12.9%	12.1%	10.6%
Adalimumab (Humira)	9.7%	8.1%	6.6%	5.2%	3.8%
Tocilizumab (Actemra)	27.6%	26.9%	25.8%	23.8%	20.3%
Etanercept (Enbrel)	26.7%	24.2%	21.5%	18.4%	14.6%

 @2019 Hong Kong Academy of Medicine. All rights reserved